Targeting ALK rearrangements in non-small cell lung cancer
Chongrui Xu, MD, PhD, Guangdong Lung Cancer Institute, Guangzhou, China, discusses current ALK inhibitors for patients with ALK-positive non-small cell lung cancer (NSCLC). There are three generations of ALK inhibitors, where crizotinib is first generation, alectinib and brigatinib are second generation and lorlatinib is third generation. Whilst there have not been any head to head comparisons of the different ALK inhibitors, lorlatinib is generally considered to result in superior survival. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
-
Category
No comments found